Biogen (BIIB)
(Delayed Data from NSDQ)
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
Pre-Market: $185.50 -0.18 (-0.10%) 9:20 AM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
Pre-Market: $185.50 -0.18 (-0.10%) 9:20 AM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Zacks News
What's in the Cards for Sunesis (SNSS) This Earnings Season?
by Zacks Equity Research
Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.
3 Tech Stocks for Growth Investors to Buy Right Now
by Benjamin Rains
Let's check out three tech stocks that came through our screen today that growth investors might want to consider at the moment...
Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Alkermes (ALKS) reports narrower-than-expected loss and sales beat in the first quarter of 2019.
Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.
Biogen (BIIB) Q1 Earnings & Sales Beat Estimates
by Zacks Equity Research
Biogen (BIIB) beat estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.
What's in Store for Celgene Corporation (CELG) Q1 Earnings?
by Zacks Equity Research
Investors are looking forward to Revlimid's performance and updates on the impending acquisition agreement with Bristol-Myers, when Celgene Corporation (CELG) reports Q1 results.
Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
While sales of Biogen's (BIIB) MS franchise are expected to decline in the first quarter of 2019 that of Spinraza are likely to increase.
Will Bristol-Myers (BMY) Disappoint This Earnings Season?
by Zacks Equity Research
Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.
Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs
by Zacks Equity Research
Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.
Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen (BIIB) closed at $232.37 in the latest trading session, marking a -0.91% move from the prior day.
Biogen (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen (BIIB) closed the most recent trading day at $237.58, moving -0.9% from the previous trading session.
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Celgene Gets Positive CHMP Nod for Revlimid Label Expansion
by Zacks Equity Research
Celgene (CELG) receives positive CHMP opinion for label expansions of IMiD medications - Revlimid and Imnovid.
Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval
by Zacks Equity Research
Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.
4 Small Biotech Stocks Likely to Witness More Upside in 2019
by Zacks Equity Research
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
Novartis (NVS) Receives FDA Approval for MS Drug Mayzent
by Zacks Equity Research
Novartis (NVS) obtains FDA approval for Mayzent for the treatment of relapsing forms of MS.
Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
by Zacks Equity Research
Key highlights of the past week are multiple study failures and other pipeline updates.
Celgene (CELG) Submits NDA for MS Drug to FDA for Review
by Zacks Equity Research
Celgene (CELG) progresses with the development of its MS candidate, as it submits an application for the same to the FDA.
AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan
by Zacks Equity Research
AbbVie's (ABBV) psoriasis drug Skyrizi gains the maiden approval in Japan for treating adults with plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis.
Biogen Stock Crashes on Termination of Alzheimer's Studies
by Zacks Equity Research
Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.
Company News For Mar 22, 2019
by Zacks Equity Research
Companies in the news are: BIIB, CAG, DRI, WSM
Jobless Claims Dip, Philly Fed Swings, Biogen (BIIB) Plummets
by Mark Vickery
Jobless claims fell back to within the long-term range to 221K, Philly Fed surprised at 13.7 (after a negative February) and Biogen's phase 3 trial is halted.
Initial Jobless Claims Decline
by Zacks Equity Research
Initial Jobless Claims Decline
Jobless Claims Dip, Philly Fed Swings, Biogen (BIIB) Plummets
by Mark Vickery
Jobless claims fell back to within the long-term range to 221K, Philly Fed surprised at 13.7 (after a negative February) and Biogen's phase 3 trial is halted.